{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-21-002825","form_type":"8-K","ticker":"PMCB","cik":"0001157075","company_name":"PharmaCyte Biotech, Inc.","filed_at":"2021-07-06T23:59:59+00:00","discovered_at":"2026-05-14T18:04:17.316685+00:00","generated_at":"2026-06-30T07:08:49.870375+00:00","sec_items":["5.07","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"PharmaCyte shareholders approve 50B common share authorization increase and bylaw amendment","bullets":["Authorized common stock increased to 50 billion shares ($0.0001 par); preferred stock to 10 million shares.","All seven director nominees elected; broker non-votes of ~701M shares.","2021 Equity Incentive Plan approved: 565.7M for, 116.4M against, 20.6M abstain.","Armanino LLP ratified as independent auditor for FY ending April 30, 2022.","Bylaw Amendment No. 4 adopted, adding cumulative voting rights for directors."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-21-002825","json":"https://secwatch.observer/filing/0001683168-21-002825.json","markdown":"https://secwatch.observer/filing/0001683168-21-002825.md","text":"https://secwatch.observer/filing/0001683168-21-002825.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1157075/000168316821002825/0001683168-21-002825-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1157075/000168316821002825/pharmacyte_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T07:08:49.870375+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}